Upcoming event
EAU UROonco: A meeting steered by the EAU Section of Oncological Urology
Back

Tag: ASCO GU22

Phase 3 MAGNITUDE study

VOLGA study

Association of RB1 mutational status with overall genomic landscape in neuroendocrine prostate cancer (NEPC)

PROpel trial

BAYOU study

TheraP trial

CYTOSHRINK study

Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations

Overall survival with darolutamide versus placebo in combination with androgen-deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer in the phase 3 ARASENS trial

Association of RB1 mutational status with overall genomic landscape in neuroendocrine prostate cancer (NEPC)